Listed

Corbus Pharmaceuticals Holdings, Inc.

CRBPNasdaqCIK 1595097HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$36.2m, Q2 FY2026
Net income−$35.0m, Q2 FY2026
Corbus Pharmaceuticals Holdings, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m6.6Research and development, Q3 FY2023, three months to 2023-09-30$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure7.0Research and development, Q4 FY2023, three months to 2023-12-31$7.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-11, accession 0000950170-25-037335. Derived: 12-month figure less the 9-month figure.Report this figure5.8Research and development, Q1 FY2024, three months to 2024-03-31$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure6.9Research and development, Q2 FY2024, three months to 2024-06-30$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure10.8Research and development, Q3 FY2024, three months to 2024-09-30$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure8.8Research and development, Q4 FY2024, three months to 2024-12-31$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure15.6Research and development, Q1 FY2025, three months to 2025-03-31$15.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure15.2Research and development, Q2 FY2025, three months to 2025-06-30$15.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure20.9Research and development, Q3 FY2025, three months to 2025-09-30$20.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure18.4Research and development, Q4 FY2025, three months to 2025-12-31$18.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure19.8Research and development, Q1 FY2026, three months to 2026-03-31$19.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure31.2Research and development, Q2 FY2026, three months to 2026-06-30$31.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Operating income$m(9.5)Operating income, Q3 FY2023, three months to 2023-09-30−$9.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure(10.1)Operating income, Q4 FY2023, three months to 2023-12-31−$10.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037335. Derived: 12-month figure less the 9-month figure.Report this figure(9.6)Operating income, Q1 FY2024, three months to 2024-03-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure(11.0)Operating income, Q2 FY2024, three months to 2024-06-30−$11.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure(15.5)Operating income, Q3 FY2024, three months to 2024-09-30−$15.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure(12.6)Operating income, Q4 FY2024, three months to 2024-12-31−$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(19.8)Operating income, Q1 FY2025, three months to 2025-03-31−$19.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(19.2)Operating income, Q2 FY2025, three months to 2025-06-30−$19.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure(24.4)Operating income, Q3 FY2025, three months to 2025-09-30−$24.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure(22.0)Operating income, Q4 FY2025, three months to 2025-12-31−$22.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(24.3)Operating income, Q1 FY2026, three months to 2026-03-31−$24.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(36.2)Operating income, Q2 FY2026, three months to 2026-06-30−$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Interest expense$m1.0Interest expense, Q3 FY2023, three months to 2023-09-30$980.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure0.9Interest expense, Q4 FY2023, three months to 2023-12-31$930.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-11, accession 0000950170-25-037335. Derived: 12-month figure less the 9-month figure.Report this figure0.8Interest expense, Q1 FY2024, three months to 2024-03-31$839.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure0.7Interest expense, Q2 FY2024, three months to 2024-06-30$652.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure0.4Interest expense, Q3 FY2024, three months to 2024-09-30$381.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure0.0Interest expense, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Net income$m(10.1)Net income, Q3 FY2023, three months to 2023-09-30−$10.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure(8.0)Net income, Q4 FY2023, three months to 2023-12-31−$8.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037335. Derived: 12-month figure less the 9-month figure.Report this figure(6.9)Net income, Q1 FY2024, three months to 2024-03-31−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure(10.0)Net income, Q2 FY2024, three months to 2024-06-30−$10.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure(13.8)Net income, Q3 FY2024, three months to 2024-09-30−$13.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure(9.5)Net income, Q4 FY2024, three months to 2024-12-31−$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(17.0)Net income, Q1 FY2025, three months to 2025-03-31−$17.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(17.7)Net income, Q2 FY2025, three months to 2025-06-30−$17.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure(23.3)Net income, Q3 FY2025, three months to 2025-09-30−$23.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure(20.6)Net income, Q4 FY2025, three months to 2025-12-31−$20.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(23.0)Net income, Q1 FY2026, three months to 2026-03-31−$23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(35.0)Net income, Q2 FY2026, three months to 2026-06-30−$35.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Diluted EPS$ per share(2.27)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$2.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figurenot reported(0.83)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure(0.90)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure(1.15)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figurenot reported(1.39)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(1.44)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure(1.90)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figurenot reported(1.23)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(1.81)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Basic EPS$ per share(2.27)Basic EPS, Q3 FY2023, three months to 2023-09-30−$2.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figurenot reported(0.83)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.83 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure(0.90)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure(1.15)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figurenot reported(1.39)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(1.44)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure(1.90)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figurenot reported(1.23)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(1.81)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure

Balance sheet

Cash and equivalents$23.4m, Q2 FY2026
Long-term debt$0, Q1 FY2024
Shareholders' equity$102.2m, Q2 FY2026
Corbus Pharmaceuticals Holdings, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m11.2Cash and equivalents, Q3 FY2023, at 2023-09-30$11.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure13.7Cash and equivalents, FY2023, at 2023-12-31$13.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-11, accession 0000950170-25-037335.Report this figure14.1Cash and equivalents, Q1 FY2024, at 2024-03-31$14.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure23.7Cash and equivalents, Q2 FY2024, at 2024-06-30$23.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure19.4Cash and equivalents, Q3 FY2024, at 2024-09-30$19.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure17.2Cash and equivalents, FY2024, at 2024-12-31$17.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure18.9Cash and equivalents, Q1 FY2025, at 2025-03-31$18.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure20.0Cash and equivalents, Q2 FY2025, at 2025-06-30$20.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure27.0Cash and equivalents, Q3 FY2025, at 2025-09-30$27.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure28.5Cash and equivalents, FY2025, at 2025-12-31$28.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure25.7Cash and equivalents, Q1 FY2026, at 2026-03-31$25.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure23.4Cash and equivalents, Q2 FY2026, at 2026-06-30$23.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Current assets$m31.2Current assets, Q3 FY2023, at 2023-09-30$31.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure23.5Current assets, FY2023, at 2023-12-31$23.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037335.Report this figure122Current assets, Q1 FY2024, at 2024-03-31$121.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure148Current assets, Q2 FY2024, at 2024-06-30$148.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure161Current assets, Q3 FY2024, at 2024-09-30$160.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure153Current assets, FY2024, at 2024-12-31$153.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure137Current assets, Q1 FY2025, at 2025-03-31$137.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure123Current assets, Q2 FY2025, at 2025-06-30$122.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure108Current assets, Q3 FY2025, at 2025-09-30$107.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure167Current assets, FY2025, at 2025-12-31$167.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure144Current assets, Q1 FY2026, at 2026-03-31$143.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure123Current assets, Q2 FY2026, at 2026-06-30$122.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Total assets$m36.3Total assets, Q3 FY2023, at 2023-09-30$36.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure28.3Total assets, FY2023, at 2023-12-31$28.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-11, accession 0000950170-25-037335.Report this figure126Total assets, Q1 FY2024, at 2024-03-31$125.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure152Total assets, Q2 FY2024, at 2024-06-30$152.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure164Total assets, Q3 FY2024, at 2024-09-30$164.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure156Total assets, FY2024, at 2024-12-31$155.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure140Total assets, Q1 FY2025, at 2025-03-31$139.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure125Total assets, Q2 FY2025, at 2025-06-30$125.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure110Total assets, Q3 FY2025, at 2025-09-30$109.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure168Total assets, FY2025, at 2025-12-31$168.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure144Total assets, Q1 FY2026, at 2026-03-31$144.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure127Total assets, Q2 FY2026, at 2026-06-30$127.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Current liabilities$m31.5Current liabilities, Q3 FY2023, at 2023-09-30$31.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure31.9Current liabilities, FY2023, at 2023-12-31$31.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037335.Report this figure25.9Current liabilities, Q1 FY2024, at 2024-03-31$25.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure24.0Current liabilities, Q2 FY2024, at 2024-06-30$24.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure11.6Current liabilities, Q3 FY2024, at 2024-09-30$11.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure11.8Current liabilities, FY2024, at 2024-12-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure11.6Current liabilities, Q1 FY2025, at 2025-03-31$11.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure13.3Current liabilities, Q2 FY2025, at 2025-06-30$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure17.1Current liabilities, Q3 FY2025, at 2025-09-30$17.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure20.7Current liabilities, FY2025, at 2025-12-31$20.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure18.1Current liabilities, Q1 FY2026, at 2026-03-31$18.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure21.5Current liabilities, Q2 FY2026, at 2026-06-30$21.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Total liabilities$m36.0Total liabilities, Q3 FY2023, at 2023-09-30$36.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure35.2Total liabilities, FY2023, at 2023-12-31$35.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-11, accession 0000950170-25-037335.Report this figure28.8Total liabilities, Q1 FY2024, at 2024-03-31$28.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure26.4Total liabilities, Q2 FY2024, at 2024-06-30$26.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure13.7Total liabilities, Q3 FY2024, at 2024-09-30$13.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure13.5Total liabilities, FY2024, at 2024-12-31$13.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure12.8Total liabilities, Q1 FY2025, at 2025-03-31$12.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure14.1Total liabilities, Q2 FY2025, at 2025-06-30$14.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure17.4Total liabilities, Q3 FY2025, at 2025-09-30$17.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure20.7Total liabilities, FY2025, at 2025-12-31$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure18.1Total liabilities, Q1 FY2026, at 2026-03-31$18.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure24.7Total liabilities, Q2 FY2026, at 2026-06-30$24.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure
Long-term debt$m0.0Long-term debt, Q3 FY2023, at 2023-09-30$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure0.0Long-term debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure0.0Long-term debt, Q1 FY2024, at 2024-03-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$m17.8Current portion of debt, Q3 FY2023, at 2023-09-30$17.8m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure15.9Current portion of debt, FY2023, at 2023-12-31$15.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure12.8Current portion of debt, Q1 FY2024, at 2024-03-31$12.8m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m0.3Shareholders' equity, Q3 FY2023, at 2023-09-30$312.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure(6.9)Shareholders' equity, FY2023, at 2023-12-31−$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-09, accession 0001193125-26-098530.Report this figure97.0Shareholders' equity, Q1 FY2024, at 2024-03-31$97.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure126Shareholders' equity, Q2 FY2024, at 2024-06-30$125.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure150Shareholders' equity, Q3 FY2024, at 2024-09-30$150.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure142Shareholders' equity, FY2024, at 2024-12-31$142.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure127Shareholders' equity, Q1 FY2025, at 2025-03-31$127.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure111Shareholders' equity, Q2 FY2025, at 2025-06-30$111.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure92.1Shareholders' equity, Q3 FY2025, at 2025-09-30$92.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure148Shareholders' equity, FY2025, at 2025-12-31$147.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure126Shareholders' equity, Q1 FY2026, at 2026-03-31$126.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure102Shareholders' equity, Q2 FY2026, at 2026-06-30$102.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure

Cash flow

Operating cash flow−$29.6m, Q2 FY2026
Capital expenditure$6.0k, Q2 FY2026
Corbus Pharmaceuticals Holdings, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(7.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123486. Derived: 9-month figure less the 6-month figure.Report this figure(6.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-11, accession 0000950170-25-037335. Derived: 12-month figure less the 9-month figure.Report this figure(8.0)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure(8.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0000950170-25-103118. Derived: 6-month figure less the 3-month figure.Report this figure(13.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277748. Derived: 9-month figure less the 6-month figure.Report this figure(10.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(16.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$16.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(16.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$16.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338274. Derived: 6-month figure less the 3-month figure.Report this figure(15.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$15.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277748. Derived: 9-month figure less the 6-month figure.Report this figure(15.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$15.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001193125-26-098530. Derived: 12-month figure less the 9-month figure.Report this figure(25.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$25.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure(29.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$29.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338274. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-07, accession 0000950170-23-060377. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-12, accession 0000950170-24-030133. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338274. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338274. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)19.41m, Q2 FY2026
Corbus Pharmaceuticals Holdings, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares4.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-304,170,881 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0000950170-23-060377.Report this figure4.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-314,181,556 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0000950170-24-054625.Report this figure4.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-304,277,701 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0000950170-24-091922.Report this figure4.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-304,423,617 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123486.Report this figure8.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-318,310,508 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0000950170-25-064507.Report this figure11.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3011,053,241 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0000950170-25-103118.Report this figure12.0Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3012,014,700 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure12.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3112,202,092 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure12.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3012,240,443 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure12.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3012,307,298 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277748.Report this figure18.7Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3118,706,622 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219707.Report this figure19.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3019,407,688 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure

Shares outstanding: 19.34mShares outstanding, period not labelled, at 2026-08-0419,341,293 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338274.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.